Automated synthesis of the 16α-[18F]fluoroestradiol ([18F]FES): minimization of precursor amount and resulting benefits
Author:
Fedorova Olga1, Orlovskaya Viktoriya1, Nadporojskii Michail2, Krasikova Raisa1
Affiliation:
1. N.P. Bechtereva Institute of the Human Brain, Russian Academy of Sciences , 9, Pavlova str., 197376 , Saint-Petersburg , Russia 2. Russian Scientific Center of Radiology and Surgical Technologies named after A.M. Granov , 70, Leningradskaya str., 197758 , Pesochny , Russia
Abstract
Abstract
The 16α-[18F]Fluoroestradiol ([18F]FES) is an established PET radiotracer for estrogen positive (ER+) breast cancer. Although the radiosynthesis is well-described, the majority of the published methods suffer from modest or irreproducible yields and time-intensive purification procedures. In view of the considerable clinical applications, development of a more efficient and faster synthesis of [18F]FES still remains a task of a significant practical importance. [18F]FES was produced by a direct nucleophilic radiofluorination of 3-O-methoxymethyl-16,17-O-sulfuryl-16-epiestriol (MMSE), followed by acidic hydrolysis using HCl/CH3CN. [18F]Fluoride retained on a QMA carb cartridge (46 mg) was eluted by solution of 1.2 mg of tetrabutylammonium tosylate (TBAOTs) in EtOH. After fluorination reaction (0.3 mg MMSE, 1 ml of CH3CN/100 °C, 5 min) [18F]FES was isolated by single-cartridge SPE purification using OASIS WAX 3cc, elution accomplished with aqueous ethanol of different concentrations. On а GE TRACERlab FX N Pro automated module [18F]FES (formulated in normal saline with 5% EtOH) was obtained in 33 ± 3% yield (n = 5, non-decay corrected) within 32 min. Reduction of precursor amount, exclusion of azeotropic drying step and simplification of purification make the suggested method readily adaptable to various automated synthesizers and offers significant cost decrease.
Funder
N.P. Bechtereva Institute of Human Brain, Russian Academy of Sciences
Publisher
Walter de Gruyter GmbH
Subject
Physical and Theoretical Chemistry
Reference39 articles.
1. van Kruchten, M., de Vries, E. G., Brown, M., de Vries, E. F. J., Glaudemans, A. W. J. M., Dierckx, R. A. J. O., Schroder, C. P., Hospers, G. A. P. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013, 14, e465; https://doi.org/10.1016/s1470-2045(13)70292-4. 2. Liao, G. J., Clark, A. S., Schubert, E. K., Mankoff, D. A. 18F-Fluoroestradiol PET: current status and potential future clinical applications. J. Nucl. Med. 2016, 57, 1269; https://doi.org/10.2967/jnumed.116.175596. 3. Mintun, M. A., Welch, M. J., Siegel, B. A. Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169, 45; https://doi.org/10.1148/radiology.169.1.3262228. 4. Peterson, L. M., Mankoff, D. A., Lawton, T., Yagle, K., Schubert, E. K., Stekhova, S., Gown, A., Link, J. M., Tewson, T., Krohn, K. A. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J. Nucl. Med. 2008, 49, 367; https://doi.org/10.2967/jnumed.107.047506. 5. Gemignani, M. L., Patil, S., Seshan, V. E., Sampson, M., Humm, J. L., Lewis, J. S., Brogi, E., Larson, S. M., Morrow, M., Pandit-Taskar, N. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J. Nucl. Med. 2013, 54, 1697; https://doi.org/10.2967/jnumed.112.113373.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|